Whereas PD-L1 levels were consistently low in baseline and on-treatment sample analyses, the seven who developed initial blast reduction followed by rapid progression exhibited high PD-L2 protein expression on AML cells. The gene discussed is PDCD1LG2; the disease is acute myeloid leukemia.